单细胞转录学揭示了瘤微环境的变化和肝细胞癌的预后基因特征
Yilin Wu1, Yangyang Zhai2, Zhilong Ding3
1School of Life Science and Food Engineering, Huaiyin Institute of Technology, Huai'an, China.
International immunopharmacology
|October 24, 2024
概括
肝细胞癌 (HCC) 的进展会改变瘤的微环境,免疫细胞的转移会影响预后. 确定了关键的基因和细胞通信通路,这表明了潜在的治疗点,如阿塞塔拉克斯用于HCC治疗.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 肝细胞癌 (HCC) 是一种流行且异质的原发性肝癌.
- HCC具有免疫抑制瘤微环境,阻碍有效治疗.
- 了解HCC的动态瘤微环境对于治疗进步至关重要.
研究的目的:
- 用单细胞RNA测序研究肝细胞癌 (HCC) 进展过程中的动态瘤微环境变化.
- 分析免疫细胞的通信,并识别HCC的预后标记基因.
- 根据已识别的基因,预测HCC的潜在治疗药物.
主要方法:
- 分析了来自HCC患者 (I-IV阶段) 的单细胞RNA转录组数据.
- 细胞组成,动态变化和细胞-细胞通信在HCC各个阶段进行了评估.
- 进行了预后模型和药物敏感性分析.
主要成果:
- 瘤微环境的组成随着HCC恶性变化而变化,标志着T细胞和髓状细胞动态的改变.
- 与癌症相关的纤维细胞 (CAF) 和T细胞基因与HCC的不良结果相关.
- 骨髓系衍生抑制细胞 (MDSCs) 增加晚期HCC,使得预测结果.
- YY1和MYC转录因子高度表达;在细胞通信中观察到显著的途径差异.
- 乙拉克斯 (Acetalax),阿洛普林醇 (Allopurinol) 和阿莫纳菲德 (Amonafide) 被确定为潜在的HCC治疗剂.
结论:
- HCC的进展显著重塑瘤微环境和免疫细胞格局.
- 特定的基因和细胞传播途径对于HCC的进展和预后至关重要.
- 已识别的治疗剂为肝细胞癌治疗提供了有前途的途径.
更多相关视频
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K


